1. Home
  2. AKRO vs MCY Comparison

AKRO vs MCY Comparison

Compare AKRO & MCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • MCY
  • Stock Information
  • Founded
  • AKRO 2017
  • MCY 1961
  • Country
  • AKRO United States
  • MCY United States
  • Employees
  • AKRO N/A
  • MCY N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • MCY Property-Casualty Insurers
  • Sector
  • AKRO Health Care
  • MCY Finance
  • Exchange
  • AKRO Nasdaq
  • MCY Nasdaq
  • Market Cap
  • AKRO 3.9B
  • MCY 3.7B
  • IPO Year
  • AKRO 2019
  • MCY N/A
  • Fundamental
  • Price
  • AKRO $50.56
  • MCY $69.70
  • Analyst Decision
  • AKRO Strong Buy
  • MCY Strong Buy
  • Analyst Count
  • AKRO 6
  • MCY 1
  • Target Price
  • AKRO $82.50
  • MCY $80.00
  • AVG Volume (30 Days)
  • AKRO 1.1M
  • MCY 269.5K
  • Earning Date
  • AKRO 08-08-2025
  • MCY 07-29-2025
  • Dividend Yield
  • AKRO N/A
  • MCY 1.83%
  • EPS Growth
  • AKRO N/A
  • MCY 32.82
  • EPS
  • AKRO N/A
  • MCY 5.16
  • Revenue
  • AKRO N/A
  • MCY $5,595,427,000.00
  • Revenue This Year
  • AKRO N/A
  • MCY $7.13
  • Revenue Next Year
  • AKRO N/A
  • MCY $7.60
  • P/E Ratio
  • AKRO N/A
  • MCY $13.44
  • Revenue Growth
  • AKRO N/A
  • MCY 16.64
  • 52 Week Low
  • AKRO $21.34
  • MCY $44.19
  • 52 Week High
  • AKRO $58.40
  • MCY $80.72
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 44.48
  • MCY 62.65
  • Support Level
  • AKRO $50.60
  • MCY $67.60
  • Resistance Level
  • AKRO $52.55
  • MCY $70.78
  • Average True Range (ATR)
  • AKRO 1.83
  • MCY 1.69
  • MACD
  • AKRO -0.35
  • MCY 0.16
  • Stochastic Oscillator
  • AKRO 17.66
  • MCY 83.56

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About MCY Mercury General Corporation

Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The Company offers the following types of automobile coverage: collision, property damage, bodily injury ("BI"), comprehensive, personal injury protection ("PIP"), underinsured and uninsured motorist, and other hazards. The Company offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages.

Share on Social Networks: